Evidence map›Paper›PMID 36245651›Full record

ArticleKidney3602022

A

Girish N Nadkarni, Dipti Takale, Bruce Neal, Kenneth W Mahaffey, Yshai Yavin, Michael K Hansen, Fergus Fleming, Hiddo J L Heerspink, Steven G Coca

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Diabetic kidney disease, biomarkers, and finerenone.Diabetes, obesity & metabolism · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Girish N NadkarniDivision of Data-Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0001-6319-4314
Dipti TakalePersistent Systems, Pune, India.
Bruce NealThe George Institute for Global Health, UNSW Sydney, Sydney, Australia.ORCID 0000-0002-0490-7465
Kenneth W MahaffeyStanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Yshai YavinJanssen Research and Development, LLC, Spring House, Pennsylvania.
Michael K HansenJanssen Research and Development, LLC, Spring House, Pennsylvania.ORCID 0000-0002-0062-0520
Fergus FlemingRenalytix, New York, New York.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-3126-3730
Steven G CocaThe Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-0928-9168
Icahn School of Medicine at Mount Sinai · USJanssen (United States) · USCenter for Clinical Research (United States) · USPersistent Systems (India) · INThe George Institute for Global Health · AUUniversity of Groningen · NL

Funding

COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
NIH HHS S10 OD026880NIH HHS S10 OD030463
6 · The paper itself

Abstract

KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.

Indexed as

Cardiovascular SystemDiabetes Mellitus, Type 2Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsCanagliflozinHumansCanagliflozinSodium-Glucose Transporter 2 Inhibitorschronic renal diseaseclinical nephrologydiabetesdiabetes mellitusdiabetic nephropathy

Identifiers

PMID36245651
PMCPMC9528375
OpenAlexW4281286855

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.